首页> 美国卫生研究院文献>The Oncologist >First Prospective Multicenter Italian Study on the Impact of the 21‐Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer

【2h】

First Prospective Multicenter Italian Study on the Impact of the 21‐Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer

机译：一项关于21基因复发评分对ER阳性/ HER2阴性乳腺癌患者辅助临床决策的影响的第一项前瞻性多中心意大利研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

获取外文期刊封面目录资料

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

Background.The Breast DX Italy prospective study evaluated the impact of the 21‐gene recurrence score (RS) result on adjuvant treatment decisions for patients with early breast cancer.

机译：背景：意大利DX乳腺癌前瞻性研究评估了21基因复发评分（RS）结果对早期乳腺癌患者辅助治疗决策的影响。

著录项

期刊名称 The Oncologist
作者
Maria Vittoria Dieci; Valentina Guarneri; Tommaso Giarratano; Marta Mion; Giampaolo Tortora; Costanza De Rossi; Stefania Gori; Cristina Oliani; Laura Merlini; Felice Pasini; Giorgio Bonciarelli; Gaia Griguolo; Enrico Orvieto; Silvia Michieletto; Tania Saibene; Paola Del Bianco; Gian Luca De Salvo; PierFranco Conte; *;
展开▼
作者单位

展开▼
年(卷),期 2018(23),3
年度 2018
页码 297–305
总页数 9
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词
Early breast cancer Adjuvant chemotherapy Estrogen receptor positive Recurrence score Treatment change;

机译：早期乳腺癌;辅助化疗;雌激素受体阳性;复发评分;治疗改变;

相似文献

外文文献
中文文献
专利

1. First Prospective Multicenter Italian Study on the Impact of the 21a??Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer [J] . Maria Vittoria Dieci, Valentina Guarneri, Tommaso Giarratano, The oncologist . 2018,第3期

机译：意大利第一个前瞻性多中心研究，研究21a ??基因复发评分对ER阳性/ HER2阴性乳腺癌患者辅助临床决策的影响
2. First Prospective Multicenter Italian Study on the Impact of the 21-Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer [J] . Dieci Maria Vittoria, Guarneri Valentina, Giarratano Tommaso, The oncologist . 2018,第3期

机译：第一次潜在的多中心意大利语研究了21-基因复发评分在辅助/海2阴性乳腺癌患者辅助临床决策中的影响
3. Prospective transGEICAM study of the impact of the 21-gene recurrence score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer [J] . AlbanellJ., GonzálezA., Ruiz-borregoM., Annals of oncology: official journal of the European Society for Medical Oncology . 2012,第3期

机译：transGEICAM的前瞻性研究对21基因复发评分测定法和传统临床病理因素对雌激素受体阳性（ER +）淋巴结阴性乳腺癌妇女辅助临床决策的影响
4. Elevated WBP2 Expression in HER2-Positive Breast Cancers Correlates with Sensitivity to Trastuzumab-Based Neo-Adjuvant Therapy: A Retrospective and Multicentric Study [C] . Yoon Pin Lim International Molecular Medicine Tri-Conference. . 2019

机译：HER2阳性乳腺癌中的WBP2表达升高与基于曲妥珠单抗的新辅助治疗的敏感性相关：回顾性和多中心研究
5. Preclinical exploration of novel small molecules as anticancer agents in triple-negative and HER2/neu-positive breast cancers. [D] . Weng, Shu-Chuan. 2008

机译：在三阴性和HER2 / neu阳性乳腺癌中作为抗癌药的新型小分子的临床前探索。
6. Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10) [O] . Bernhard C. Pestalozzi, Christoph Tausch, Konstantin J. Dedes, 2017

机译：瑞士肿瘤委员会采用21基因复发评分（SAKK 26/10）为ER阳性/ HER2阴性的早期乳腺癌患者提供辅助治疗建议
7. Pooled analysis of prospective European studies assessing the impact of using the 21-gene Recurrence Score assay on clinical decision making in women with oestrogen receptor–positive, human epidermal growth factor receptor 2–negative early-stage breast cancer [O] . Albanell Joan, Svedman Christer, Gligorov Joseph, 2016

机译：欧洲前瞻性研究的汇总分析，评估了使用21基因复发评分法对雌激素受体阳性，人表皮生长因子受体2阴性的早期乳腺癌女性临床决策的影响

First Prospective Multicenter Italian Study on the Impact of the 21‐Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅